Ligand Pharmaceuticals

Yahoo Finance • 4 days ago

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 18 days ago

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the “Company”) Co-development Agreement with US I... Full story

Yahoo Finance • last month

Notable ETF Inflow Detected - JPLD

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPLD ETF (Symbol: JPLD) where we have detected an approximate $314.4 million dollar inflow -- that's a 14.2%... Full story

Yahoo Finance • 2 months ago

A Fresh Look at Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Note Offering and Capital Structure Shift

If you have been watching Ligand Pharmaceuticals (LGND), the $400 million convertible note offering completed this month might have made you sit up and pay attention. Not only did the company finalize this sizable senior unsecured notes de... Full story

Yahoo Finance • 2 months ago

Ligand Pharmaceuticals stock hits 52-week high at $157.54

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), with a market capitalization of $3.1 billion, has reached a significant milestone with its stock hitting a 52-week high of $157.54. According to InvestingPro analysis, the stock is curren... Full story

Yahoo Finance • 2 months ago

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcom... Full story

Yahoo Finance • 2 months ago

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “note... Full story

Yahoo Finance • 2 months ago

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “no... Full story

Yahoo Finance • 2 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth

Ligand Pharmaceuticals (NASDAQ:LGND [https://www.chartmill.com/stock/quote/LGND]) reported second-quarter 2025 earnings that surpassed analyst expectations, driven by strong royalty revenue growth. Despite the beat, the stock showed muted... Full story

Yahoo Finance • 2 months ago

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1... Full story

Yahoo Finance • 2 months ago

Ligand Pharmaceuticals Q2 2025 Earnings Preview

* Ligand Pharmaceuticals (NASDAQ:LGND [https://seekingalpha.com/symbol/LGND]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is $1.42 [https://seekingalpha.com/sym... Full story

Yahoo Finance • 2 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private p... Full story

Yahoo Finance • 3 months ago

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference... Full story

Yahoo Finance • 3 months ago

3 Stocks That May Be Trading Below Estimated Value In July 2025

As the U.S. stock market hovers near record highs, investors remain cautious amid ongoing trade policy uncertainties and fluctuating economic indicators. In this environment, identifying stocks that may be trading below their estimated val... Full story

Yahoo Finance • 3 months ago

Top 3 small-cap stock picks while navigating trade uncertainty

Small-cap stocks are positioned for gains and trading at a discount compared to their large-cap peers, Villere & Co. portfolio manager Sandy Villere tells the Market Domination team. Watch the video above to hear more from Villere about to... Full story

Yahoo Finance • 3 months ago

Ligand Pharmaceuticals director Kozarich sells $116k in stock

Director John W. Kozarich of Ligand Pharmaceuticals INC (NASDAQ:LGND) sold 934 shares of common stock on July 10, 2025, at a price of $125.0, totaling $116750. The transaction occurs as LGND trades near its 52-week high of $129.90, with... Full story

Yahoo Finance • 3 months ago

Ligand earns $5 million milestone as partner launches molluscum treatment

JUPITER, Fla. - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), currently trading near its 52-week high with a market capitalization of $2.36 billion, announced Thursday it has received a $5 million milestone payment following partner P... Full story

Yahoo Finance • 3 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical... Full story

Yahoo Finance • 3 months ago

Ligand completes merger, Pelthos to launch molluscum treatment

JUPITER, Fla. - Ligand Pharmaceuticals Incorporated (Nasdaq:LGND), a $2.17 billion market cap company with a strong financial health score according to InvestingPro, announced Wednesday the completion of its merger between subsidiary LNHC,... Full story

Yahoo Finance • 6 months ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription med... Full story